{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336057","form_type":"8-K","ticker":"LFST","cik":"0001845257","company_name":"LifeStance Health Group, Inc.","filed_at":"2026-08-06T00:21:23+00:00","discovered_at":"2026-08-06T10:10:00.467233+00:00","generated_at":"2026-08-06T10:10:19.056517+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"LifeStance Q2 revenue up 26% to $435.4M, net income $23.6M, raises FY2026 guidance, announces $100M buyback","bullets":["Revenue $435.4M (+26% YoY), net income $23.6M vs loss $3.8M.","Adjusted EBITDA $66.0M (+94% YoY), margin 15.2% vs 9.8%.","Clinician base 8,542 (+11% YoY), visit volumes 2.6M (+19%).","FY2026 revenue guidance raised to $1.685-1.725B, Adjusted EBITDA $215-235M.","Board approved new $100M share repurchase program, replacing prior $100M program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336057","json":"https://secwatch.observer/filing/0001193125-26-336057.json","markdown":"https://secwatch.observer/filing/0001193125-26-336057.md","text":"https://secwatch.observer/filing/0001193125-26-336057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845257/000119312526336057/0001193125-26-336057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845257/000119312526336057/lfst-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T10:10:19.056517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}